DACIKAST is an NS5A inhibitor that prevents hepatitis C virus (HCV) replication and slows disease progression.
Recommended for:
Adults diagnosed with chronic HCV infection
Combination therapy with sofosbuvir (± ribavirin)
Patients with or without compensated cirrhosis
All HCV genotypes (1 through 6)
Treatment of chronic hepatitis C infection in adults, in combination with other antiviral agents
Take once daily, orally, with or without food, as part of a combination antiviral regimen (commonly with sofosbuvir). Duration of therapy depends on HCV genotype and liver status.
Contraindications:
Known hypersensitivity to daclatasvir or its excipients
Pregnancy and breastfeeding
Use in children is not recommended
Side effects:
Fatigue, headache
Nausea, insomnia
Anaemia (especially with ribavirin)